IMMUTEP Ltd
PRRUF- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001506184
No open-market purchases or sales by IMMUTEP Ltd insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Other share classesIMMP
Key figures
- Market capADS ratio not in SEC data
- –
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026
- 0
- 13F valueReported value at the end of Q2 2026
- $0
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in AUD.
- Revenue, FY2025
- AUD 10.3M
- +31.8% year over year
- Net income, FY2025
- AUD -61.4M
- No comparable prior period
- Free cash flow, FY2025
- AUD -62.1M
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 15, 2026.
- Short interest
- 14.2M
- Shares sold short
- Change
- −1.10M
- −7.2% vs. previous
- Days to cover
- > 999
- Above FINRA's cap of 999.99 days
Superinvestors holding PRRUF, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding PRRUF at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by IMMUTEP Ltd insiders from Form 4, newest first.
No open-market purchases or sales by IMMUTEP Ltd insiders are on file.
Top 10 13F holders, Q2 2026
View all: Top 10 13F holders, Q2 2026The largest institutional positions in IMMUTEP Ltd at the end of Q2 2026; share changes are against Q1 2026.
No institution reported holding PRRUF in 13F filings for Q2 2026.